ArticlePediatric nephrology (Berlin, Germany)1987
Cyclosporin in the treatment of idiopathic nephrotic syndrome in children.
Article in Pediatric nephrology (Berlin, Germany), 1987. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 68 citations in OpenAlex.
- Steroid-resistant, cyclosporine-responsive, relapsing nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 1995Trial
- Comparison of cyclosporin and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. The French Society of Paediatric Nephrology.Pediatric nephrology (Berlin, Germany) · 1992Trial
- The treatment of minimal change nephrotic syndrome: lessons learned from multicentre co-operative studies.European journal of pediatrics · 1991Trial
- Practice variation in the use of steroid-sparing therapies in childhood steroid-sensitive nephrotic syndrome: results from a prospective cohort study.Pediatric nephrology (Berlin, Germany) · 2025Observational
- Intravenous cyclophosphamide therapy in children with calcineurin inhibitor-resistant steroid-resistant nephrotic syndrome in a resource-limited setting.Pediatric nephrology (Berlin, Germany) · 2024Article
- The safety of cyclosporine and tacrolimus in pediatric nephrotic syndrome patients: a disproportionate analysis based on the FAERS database.Frontiers in pediatrics · 2024Article
- History of Nephrotic Syndrome and Evolution of its Treatment.Frontiers in pediatrics · 2016Review
- Chapter 3: Steroid-sensitive nephrotic syndrome in children.Kidney international supplements · 2012Article
- Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome.Clinical journal of the American Society of Nephrology : CJASN · 2009Article
- Cyclosporin A in refractory idiopathic nephrotic syndrome: 5 years clinical experience.Postgraduate medical journal · 1994Article
- Long-term low-dose cyclosporin A in steroid dependent nephrotic syndrome of childhood.European journal of pediatrics · 1992Article
- Effect of cyclosporin A on proteinuria in patients with Alport's syndrome.Pediatric nephrology (Berlin, Germany) · 1992Article
- Management of nephrotic syndrome in childhood.Drugs · 1991Review
- Ciclosporin treatment in children with steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 1990Article
- Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents.Pediatric nephrology (Berlin, Germany) · 1990Article
- Serum interleukin-2 levels in a patient with focal segmental glomerulosclerosis. Relationship to clinical course and cyclosporin A therapy.Pediatric nephrology (Berlin, Germany) · 1990Article
- Immunosuppressive therapy in the nephrotic syndrome in children.Pediatric nephrology (Berlin, Germany) · 1989Review
- Cyclosporin A treatment in children with minimal change nephrotic syndrome and focal segmental glomerulosclerosis.Klinische Wochenschrift · 1988Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thirty-five children (12 girls, 23 boys), aged from 1 year and 5 months to 14 years at the onset of idiopathic nephrotic syndrome, received cyclosporin A (CyA) because of steroid toxicity or failure to respond to steroids. The initial oral dose was 6 mg/kg per day and this was adjusted to obtain trough plasma levels of 50-150 ng/ml. The duration of treatment was between 2 and 8 months. In patients who responded to CyA treatment, the dosage was tapered off; treatment was stopped if found to be ineffective. Of the 35 children, 20 were frequent-relapsing steroid responders who suffered serious side-effects from steroid therapy. Seventeen of them either went into remission or did not relapse despite the withdrawal of prednisone. Prednisone doses could be lowered but not stopped in 1 patient and the remaining 2 patients relapsed when prednisone was tapered off. At the final examination, 10 of the 12 children in whom CyA was tapered off and who had initially responded to CyA had relapsed. A second course was given to these 10 patients and 3 failed to respond. Five children were partial steroid responders and CyA induced a remission in 1 and a partial remission in another. Among the 10 children who were steroid resistant, only 1 responded to CyA, 2 had a partial response and 7 failed to respond to CyA. A reduction of glomerular filtration rate occurred in 8 patients, 7 of whom had either persistent nephrotic syndrome or were in relapse, which suggests that factors other than CyA nephrotoxicity may have been operative. Complete reversal occurred in only 4 patients. Significant histological changes, likely to be related to CyA, were seen in 2 repeat renal biopsies out of the 11 performed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.